UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________________________________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of ~~The~~the Securities Exchange Act of 1934

~~February 13, 2015~~____________________________________________________________

Date of Report (Date of earliest event reported): February 22, 2016

GALILEO LIFE SCIENCES, INC.

(Exact Name of Registrant as Specified in Charter)

MODERN MOBILITY AIDS, INC.

(Exact name of registrant as specified in its charter)

Nevada	333-168983	27-4677038
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

Suite 625, 4211 Yonge Street

Toronto, ON. Canada M2P 2A9

Attn: John M Rosenthal, CPA, CA, LPA

(Address of Principal Executive offices)(Zip Code)

(416) 636-7500 (Registrant's telephone number Including area code)

(Former name or former address, if changed since last report)

First Canadian Place, Suite 350, Toronto, Ontario M5X 1C1

Nevada	333-168983	27-4677038
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

First Canadian Place, Suite 350 Toronto, Ontario Canada		M5X1C1
(Address of principal executive offices)		(Zip Code)

~~Attn~~Registrant’s telephone number, including area code: ~~Preston~~ J.(586) ~~Shea~~ 530-5605

~~Check~~Copies ~~the appropriate box below if the Form 8-K filing is intended~~ to ~~simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below)~~:

~~¨ Written~~Arthur ~~communication~~S. ~~pursuant~~Marcus, ~~to Rule 425 under the Securities Act (17 CFR 230~~Esq.~~425)~~

¨ ~~Soliciting~~Sichenzia ~~material~~Ross ~~pursuant~~Friedman toFerence ~~Rule 14a-12 under the Securities Act (17 CFR 240.14a-12)~~LLP

¨ ~~Pre-commencement~~61 ~~communications~~Broadway, ~~pursuant~~32nd ~~to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))~~Floor

¨ ~~Pre-commencement~~New ~~communications~~York, ~~pursuant~~New toYork ~~Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))~~10006

(212) 930-9700

(212) 930-9725 (fax)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 54.~~02 Departure~~01 Changes ofin ~~Directors~~Registrant’s orCertifying ~~Principal Officers; Election of Directors; Appointment of Principal Officers~~Accountant.

~~Appointment~~(a) Cutler & Co., LLC (“Cutler”) has informed Galileo Life Sciences, Inc. (the “Company”) that it has merged its SEC auditing practice with Pritchett, Siler & Hardy PC (“Pritchett Siler”). As a result of the transaction, Cutler has resigned as the Company’s independent registered public accounting firm. On February 11, 2016, the Company’s Board of Directors approved the engagement of Pritchett Siler as the Company’s independent registered public accounting firm.

~~Effective~~The ~~February~~audit ~~13,~~reports ~~2015, our Board~~ of ~~Directors~~Cutler ~~increased~~on the ~~number~~consolidated offinancial ~~members~~statements ~~who~~of ~~serve on~~ the ~~Board~~Company offor ~~Directors~~the toyears ~~five~~ended ~~persons~~June ~~and appointed Mr. John Rosenthal~~30, ~~Dr.~~2014 ~~Baseer~~and ~~Uddin~~2013 ~~Khan~~did ~~and~~not ~~Ken~~contain ~~(Khahn)~~any ~~Pham~~adverse asopinion ~~members~~or disclaimer of ~~our~~opinion, ~~Board~~nor ofwas ~~Directors~~they ~~(the~~qualified ~~“New~~or ~~Directors”).~~modified ~~Effective~~as ~~February~~to 13uncertainty, ~~2015~~audit scope, ~~Mr.~~or ~~Kenneth~~accounting ~~Pinckard~~principles ~~resigned~~except asthat the ~~Chief~~audit ~~Executive~~reports ~~Officer~~contained ~~and~~an auncertainty ~~director~~about of the Company’s ~~and~~ability ofto ~~its~~continue ~~subsidiaries~~as a going concern.

InDuring ~~connection~~the years ~~with~~ended ~~Mr.~~June ~~Pinckard’s~~30, ~~resignation~~2014 ~~as an executive officer~~ and ~~director of the Company~~2013, the ~~parties~~interim ~~agreed~~period tothrough aSeptember ~~termination~~30, of2014 ~~his~~and ~~employment~~subsequently ~~agreement~~through ~~with~~February ~~the Company. The Company has agreed to pay a total of $65~~11,~~000~~ 2016 (~~USD~~i) inthere ~~consideration~~were ofno ~~all~~disagreements ~~services~~with ~~rendered~~Cutler ~~prior~~on toany ~~his~~matter ~~termination,~~ of ~~which~~accounting ~~$45,000~~principles ~~(USD)~~or ~~was paid on the date he resigned and $20~~practices,~~000~~ ~~(USD)~~financial ~~will~~statement ~~be paid within 90-days thereafter (the “90-Day Payment”). Furthermore~~disclosure, ~~the~~or ~~parties~~auditing ~~agreed~~scope ~~that~~or ~~out~~procedures ~~of 10~~that,~~000,000~~ ~~shares~~if ofnot ~~the~~resolved ~~Company~~to Cutler’s ~~common stock previously issued to him in December of 2014~~satisfaction, ~~2,500,000 shares~~ would behave ~~returned~~caused toCutler ~~the Company~~ to bemake ~~canceled~~reference ~~and~~in ~~3,500,000~~connection ~~shares~~to ~~will~~their beopinion ~~held in escrow~~ to ~~secure~~ the ~~90-Day~~subject ~~Payment~~matter ~~and~~of ~~provided~~the ~~such~~disagreement ~~payment is timely made, will be canceled thereafter. The Company~~ and ~~Mr.~~(ii) ~~Pinckard~~there ~~agreed~~were ~~that~~no he“reportable ~~would~~events” ~~retain~~as ~~ownership~~defined ofin ~~the~~Item ~~remaining~~304(a)(1)(v) ~~4,000,000 shares~~ of ~~the~~Regulation ~~Company’s common stock~~S-K.

~~None~~The ofCompany ~~the~~has ~~New~~provided ~~Directors~~Cutler ~~have~~with a ~~family~~copy ~~relationship~~of ~~with~~this ~~any~~Current ~~executive~~Report ~~officer~~on orForm ~~director~~8-K ofand ~~the~~requested ~~Company~~that orCutler ~~persons~~furnish ~~nominated~~the orCompany ~~chosen~~with bya ~~the~~letter ~~Company~~addressed to ~~become~~the ~~directors~~Securities orand ~~officers.~~Exchange ~~There~~Commission isstating nowhether ~~arrangement~~it oragrees ~~understanding~~with ~~pursuant~~the tostatements ~~which~~made ~~any~~by ofthe ~~them~~Company ~~were~~herein ~~appointed~~and, aif ~~member~~not, ofstating the ~~Board~~respects ofin ~~Directors~~which ~~nor~~it isdoes ~~the~~not ~~Company~~agree. ~~aware~~The ofletter ~~any~~from ~~transaction~~Cutler ~~requiring~~to ~~disclosure~~the ~~under~~Securities ~~Item~~and ~~404(a)~~Exchange Commission dated as of ~~Regulation~~February ~~S-K~~22, ~~with~~2016, ~~respect~~is attached as Exhibit 16.1 to ~~the~~this ~~New~~Current ~~Directors~~Report.

~~Resume~~(b) As noted above, on February 11, 2016, the Company’s Board of ~~John~~Directors ~~Rosenthal~~approved the engagement of Pritchett Siler as the Company’s independent registered public accounting firm. During the years ended June 30, ~~CPA~~2014 and 2013, CAthe interim period through September 30, ~~LPA~~2014 and subsequently through February 11, 2016, neither the Company nor to the Company’s knowledge anyone acting on behalf of the Company consulted with Pritchett Siler regarding either (i) the application of accounting principles to a specified transaction (either completed or proposed), (ii) the type of audit opinion that might be rendered on the Company’s financial statements, or (iii) any matter that was either the subject matter of a “disagreement,” as described in Item 304(a)(1) of Regulation S-K, or a “reportable event.”

~~Mr.~~Item ~~Rosenthal currently is a senior partner of RZN, LLP Chartered Professional Accountants & Licensed Public Accountants~~9. ~~Mr.~~01 Financial ~~Rosenthal~~Statements ~~provides general business, accounting~~ and ~~auditing services for his clients, including in connection with mergers and acquisitions, restructurings, strategic planning, and litigation support services~~Exhibits. From 1980 to 1982, Mr. Rosenthal was a Partner at Wm. Eisenberg & Co., Chartered Accountants. Prior to this, Mr. Rosenthal was an accounting and auditing Manager, from 1978 to 1890, and staff accountant, from 1974 to 1978, at Wm. Eisenberg & Co. Mr. Rosenthal has served as director to various organizations.

~~Resume of Dr. Baseer Uddin Khan~~(d) Exhibits

Dr. Khan has more than fifteen years of medical experience as an Ophthalmologist. Dr. Khan is a specialist in the field of Ophthalmology with over ten appointments as a medical professional notably for Mount Sinai Hospital (Toronto, Canada), Southlake Regional Health Centre (Newmarket, Ontario), and North York General Hospital (Toronto, Ontario).

Exhibit No.	Exhibit

16.1	Letter from Cutler & Co., LLC, dated February 22, 2016.

Dr. Khan is an internationally recognized surgeon, researcher, and consultant. He is an Assistant Professor at the University of Toronto and served as Executive Lead Physician, Eye Institute, Southlake Regional Hospital, Newmarket, Ontario for five years. Dr. Khan founded, own and operates several eye clinics in Canada, including the largest private ophthalmic practice in the Greater Toronto Area (Clarity Eye Institute).. He is also a managing partner of Shura Management and the CIO of its subsidiary, Oneview Procurement Solutions.

~~Resume of Kenneth (Khanh) Pham, B. Eng, MBA, CPA, CMA~~SIGNATURES

Mr. Pham is a finance and operations professional with over 15 years of experience in the private and public sector. He has served as the vice president of operations for MDRM since August 2014. From November 2011 through July 2013, Mr. Pham was the Chief Financial Officer/Corporate controller of Top Hat Monocle Corp. where he was responsible for budgetary planning and cost management and as a member of the senior management team was responsible for the growth of the company from 10 to 80 employees as well as two successful rounds of venture capital fund raising. Prior to this Mr. Pham has also worked for Deloitte & Touche LLP and Ernst & Young LLP.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		MODERN MOBILITY AIDS, INC.
	GALILEO LIFE SCIENCES, INC.
Date: February 20, 2015		(Registrant)
Date: February 22, 2016	By:	/s/ Declan French
		/s/ Preston J. Shea
		Declan French
		Preston J. Shea, Chief Financial Officer
		Chief Executive Officer

Filing Compare · Modern Mobility Aids, Inc.